Boehringer Ingelheim, the global-leading transnational animal protection enterprise hit a milestone on January 20: Animal Vaccine Production Base in China Medical City (Hereinafter referred to as "Taizhou factory") was launched officially, and the first product of this base- the live vaccine "Lanfulai" for porcine reproductive and respiratory syndrome has been officially supplied to Chinese market.
Founded in 1885, Boehringer Ingelheim is one of the world’s top 20 pharmaceutical enterprises and a leader in global swine vaccine area. Swine vaccines supplied to Chinese market were all from abroad previously, which were produced by Boehringer Ingelheim’s USA factory.
Boehringer Ingelheim’s Taizhou factory took the lead in localized production of live vaccine "Lanfulai" for porcine reproductive and respiratory syndrome. "Lanfulai", developed and produced by Boehringer Ingelheim was used and praised widely since its global listing in 1994. The product was safe, effective and able to provide good cross protection with more than 1 billion use across the world. After domestication of "Laifulai" vaccines, Taizhou factory will continue to produce more vaccine products independently researched and developed by Boehringer Ingelheim in China, whose technology was transferred from USA factory.